

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A drug, containing:

~~metabolic product biomass~~ prepared by incubating *Rhodopseudomonas capsulatas* FERMBP-7434 strain ~~a photosynthetic bacterium~~ together with a lactic acid bacterium ~~so as to cause the photosynthetic bacterium to produce a biomass comprising~~ a viscous material; ~~wherein after being subjected to water-washing and subsequently to acid hydrolysis, the biomass has a glucose content ranging from 0.8 to 3.3 weight %, a ribose content ranging from 0.2 to 1.0 weight %, a rhamnose content ranging from 0.4 to 2.0 weight %, and a fucose content of 0.6 weight % or less~~
the photosynthetic bacterium being *Rhodopseudomonas capsulatas* FERMBP-7434 strain.

2. (currently amended) The drug as set forth in Claim 1, wherein:

the ~~biomass metabolic product~~ contains ~~bacteriochlorophyll~~ *bacteriochlorophyll* in a range of from 0.2 to 3.0 ~~weight % (weight %)~~.

3. (currently amended) The drug as set forth in Claim 1, wherein:

the ~~biomass metabolic product~~ contains ~~bacteriochlorophyll~~ *bacteriochlorophyll* in a range of from 0.6 to 1.9 ~~weight % (weight %)~~.

4. (currently amended) The drug as set forth in Claim 1, wherein:

the ~~biomass metabolic product~~ contains a carotinoid material in a range of 0.5 to 7.5 ~~$\mu\text{mol/g}$ ($\mu\text{mol/g}$)~~.

5. (currently amended) The drug as set forth in Claim 1, wherein:

the ~~biomass metabolic product~~ contains a carotinoid material in a range of 2.4 to 4.0 ~~$\mu\text{mol/g}$ ($\mu\text{mol/g}$)~~.

6. (currently amended) The drug as set forth in Claim 1, wherein:

after being subjected to acid hydrolysis, the ~~biomass-metabolic product~~ has a glucose content ~~contents (weight %)~~ ranging from 2.4 to 7.5 weight %, a ribose content ~~contents (weight %)~~ ranging from 0.3 to 1.1 weight %, a rhamnose content ~~contents (weight %)~~ ranging from 1.0 to 3.3 weight %, and a fucose content ~~contents (weight %)~~ ranging from 0.6 to 2.6 weight %.

7. (currently amended) The drug as set forth in Claim 1, wherein:

after being subjected to acid hydrolysis, the ~~biomass-metabolic product~~ has a glucose content ~~contents (weight %)~~ ranging from 3.5 to 6.5 weight %, a ribose content ~~contents (weight %)~~ ranging from 0.4 to 1.0 weight %, a rhamnose content ~~contents (weight %)~~ ranging from 1.2 to 3.0 weight %, and a fucose content ~~contents (weight %)~~ ranging from 0.8 to 2.4 weight %.

Claim 8 (canceled) The drug as set forth in Claim 1, wherein:

9. (currently amended) The drug as set forth in Claim 1, wherein:

after being subjected to water-washing and subsequently to acid hydrolysis, the ~~biomass-metabolic product~~ has a glucose content ~~contents (weight %)~~ ranging from 1.0 to 3.0 weight %, a ribose content ~~contents (weight %)~~ ranging from 0.3 to 0.9 weight %, a rhamnose content ~~contents (weight %)~~ ranging from 0.5 to 1.6 weight %, and a fucose content ~~contents (weight %)~~ of 0.5 weight % or less.

Claims 10-13 (cancel)

14. (currently amended) The drug as set forth in Claim 1, wherein:

the lactic acid bacterium is Lactobacillus ~~Lactobacillus~~ spp.

15. (currently amended) The drug as set forth in Claim 1, wherein:

the lactic acid bacterium is Lactobacillus bulgarius ~~Lactobacillus bulgarius~~.

16. (currently amended) A method of manufacturing a drug, comprising the steps of:

incubating in a liquid medium *Rhodopseudomonas capsulatas* FERMBP-7434 strain ~~a photosynthetic bacterium~~ together with a lactic acid bacterium ~~so as to cause the photosynthetic bacterium~~ to produce a biomass comprising a viscous material in the ~~the photosynthetic bacterium~~ to produce a biomass comprising a viscous material in the ~~the photosynthetic bacterium being Rhodopseudomonas capsulatas FERMBP-7434 strain~~; and

separating the biomass comprising a viscous material ~~a metabolic product~~ from the liquid medium.